

SABVEST CAPITAL LIMITED

Incorporated in the Republic of South Africa

Registration number 2020/030059/06

ISIN: ZAE000283511

JSE share code: SBP

(“Sabcap”)

TERMINATION OF SABCAP’S PROPOSED INDIRECT INVESTMENT IN ASCENDIS MEDICAL THROUGH APEX

Sabcap shareholders are referred to:

- The Sabcap announcement on 3 February 2022 released on the JSE Stock Exchange News Service (SENS) advising that Apex Partners Holdings (Pty) Limited (Apex), in which Sabcap has a 44,8% interest, had provided debt refinancing to Ascendis Health Limited (Ascendis) in January 2022 and had agreed to acquire the entities through which the business known as “Ascendis Medical” operates (the Medical Transaction).
- The Ascendis announcement released on SENS on 17 May 2022 advising that it had secured new debt facilities and had repaid existing debt providers including Apex.
- The Ascendis announcement released on SENS today advising that the Medical Transaction has been terminated.

Sabcap shareholders are advised that the debt repayment to Apex comprised all capital plus interest, financial guarantees provided by Sabcap on behalf of Apex for a portion of the debt refinancing and the Medical Transaction have been released, and the termination of the Medical Transaction was by mutual agreement between the parties.

Sandton

27 June 2022

Sponsor

RAND MERCHANT BANK (A division of FirstRand Bank Limited)